Itamar Medical Announces Closing of Public Offering of American Depositary Shares and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
Itamar Medical Ltd. (Nasdaq: ITMR) announced the closing of its public offering of 3,506,499 American Depositary Shares (ADSs) at a price of $22.75 per ADS, generating approximately $50 million in gross proceeds for the company. The offering included the full exercise of the underwriters’ option for an additional 457,369 ADSs. The company sold 2,196,499 ADSs, while a shareholder sold 1,310,000 ADSs. The offering is expected to support the company’s focus on non-invasive devices for diagnosing sleep disorders.
- Gross proceeds of approximately $50 million will support business growth.
- Increased liquidity may enhance R&D efforts and product development.
- Dilution risk for existing shareholders due to the issuance of new ADSs.
CAESAREA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the closing of its public offering of 3,506,499 American Depositary Shares (“ADSs”), which includes the full exercise of the underwriters’ option to purchase additional 457,369 ADSs at a public offering price of
Piper Sandler, Cowen and SVB Leerink acted as joint bookrunners for the offering.
A registration statement on Form F-3, including a base prospectus, relating to the offering of the ADSs by the Company was filed with the SEC on November 17, 2020 and declared effective by the SEC on December 2, 2020, and a registration statement on Form F-3, including a base prospectus, relating to the offering of ADSs by the Selling Shareholder was filed on January 22, 2021 and declared effective by the SEC on January 29, 2021. A copy of the prospectus supplement and the accompanying prospectuses relating to this offering, when available, may also be obtained from Piper Sandler & Co. 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Itamar Medical Ltd.
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders. Itamar Medical commercializes a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets. Itamar Medical offers a Total Sleep Solution to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare system costs.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes" "expects," "anticipates," "intends," "estimates," "plans", and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of the Company's control and actual results, expressed or implied by such forward-looking statements, could differ materially from the Company's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by the Company in reports filed with, or furnished to, the U.S. Securities and Exchange Commission (“SEC”) and the Israel Securities Authority (“ISA”), including the Company’s latest Form 20-F and its registration statements on Form F-3 relating to this offering, which are each accessible on the SEC’s website at www.sec.gov. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Investor Relations Contact
Leigh Salvo
Gilmartin Group
Phone: +1-415-937-5412
investors@itamar-medical.com
FAQ
What is the size of Itamar Medical's recent public offering?
What are the gross proceeds from the Itamar Medical offering?
What is the price per ADS in Itamar Medical's offering?
How many ADSs did Itamar Medical sell during the offering?
What is the impact of the public offering on Itamar Medical shareholders?
